Register Here

Lead Sponsor

Imaging Endpoints

Executive Sponsors

Parexel
Personalis

Associate Sponsors

Cello Health
Scimega

Novel Technology Sponsor

Axiom Healthcare Services

Exhibitors

Rules-Based Medicine

Educational Partners

Alliance for Regenerative Medicine
Center for Biotechnology
Journal of Immunotherapy and Precision Oncology (JIPO)

Supporting Partner

Savvy

Media Partners

Big 4 Bio

Overview

IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

The 8th Annual Immuno-Oncology 360° Delivers Three Key Benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology
  3. Presentations on the latest data impacting the science, clinical and business advancements in Immuno-Oncology 

2022 Keynotes

VIP Patient Speaker:
IO Combination Trial Journey

2022 Strategic Advisors

2022 Key Topic Areas

 

  • Discovery/Preclinical Science
  • Cell & Gene Therapy
  • Translational Science
  • Bispecifics
  • Clinical Developments
  • Neoadjuvant/Adjuvant Data
  • Emerging Biomarkers
  • IO Combinations
  • Clinical Operations
  • Business Developments
  • Imaging Advancements
  

 

 

Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
  • Partner to expand technology platforms to develop therapeutics at an accelerated rate
  • Receive the latest pre-clinical, translational and clinical data from academia and industry
  • Create and prioritize strategies targeted toward specific tumor types
  • Identify and gain a greater understanding of what assets are available for potential combinations
  • Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
  • Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
  • Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

 

 

Join the conversation early and become part of the IO360° community by following us on LinkedIn and by following the conference hashtag #IO360nyc. If you are interested in participating in the 8th Annual Immuno-Oncology 360° 2022 program, please contact us at service@tcfllc.org. Thank you.

Sincerely,​

kate-bw-3

Kate Woda
Conference Director

 Valerie Bowling New

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Strategic Partnerships

 elizabeth-bard-bw-2

Elizabeth Bard
Senior Strategic Partnership Manager

Bre Bugbee
Senior Marketing Manager

Adam Kolanko
Strategic Partnership Manager
Meg

Meg Gould
Senior Conference Planner

Danny McCarthy
IO360° Writer/Editor

Testimonials

  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, MD, PhD, Merck

  • "I really enjoyed it and connecting with some really interesting and inspiring people with whom I'm sure this is just the beginning of long standing interactions."

    - Jacqueline Karmel, Roche

  • "Thank you again for the amazing invitation, it was truly my pleasure to be able to participate in the excellent event you organized."

    - Christine Ward, BMS

  • "IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"

    - Jim Mansfield, PerkinElmer

  • "Congratulations again on the excellent program for the Immuno-Oncology 360° meeting. It was truly well coordinated and the topics were fantastic!"

    - Gilson Baia, PhD, Champions Oncology

  • "Really good, well-rounded and novel content. Congratulations on filling the house beyond capacity and for securing such an impressive speaking faculty."

    - Eileen Daniels, Nektar Therapeutics

  • "Thank you for a great conference!"

    - Elena Spanjaard, Pfizer

  • "Your team did a wonderful job in putting together an interesting and relevant program."

    - Lew Bender, Intensity Therapeutics

  • "It was a great conference and I was happy to be a part of it."

    - Anna Pavlick, DO, MD, NYU Cancer Center